Clinical Trial Search

Primary: Change in Systolic Blood Pressure From Baseline to 3 Months for APOL1 Negative Participants — -3.7; -3.1 mmHg — p=0.4852

Primary: The Difference Between Two Baseline Fluorine-18-labeled Fluoro-misonidazole (18F-FMISO) Scans — 0; 0 unitless

Primary: Primary Outcome: Program Satisfaction as Assessed by the Acceptance Questionnaire After First Intervention Session — 86; 91 Participants

Primary: Change in Average Steps Per Day From Baseline Week to Week 12 — 4224; 4786; 3654; 2626 steps/day — p=0.418

Primary: Number of Instances of Potentially Unattended Psilocybin-related Distress During Psilocybin Sessions. — 0 Events

Primary: Change in Pain Score on the Numerical Rating Score (NRS) — 2.2; 1.3 units on a scale

Primary: Mean HbA1c Levels — 8.0; 7.3; 7.9; 7.6 percentage of glycated hemoglobin

Primary: Percentage of Patients With mRS 0-3 — 39; 27 Participants

Primary: Change From Baseline in Apnea-Hypopnea Index (AHI) — -25.25; -5.25; -29.27; -5.51 events per hour — p=<0.001

Primary: Phosphorylation of STAT-3 in MDSC (Myeloid-derived Suppressor Cells) — 2.162; 2.025 STAT3 archsinh ratio — p=0.5490

Primary: Number of Participants With Positive Localization of Phosphaturic Mesenchymal Tumors (PMTs) — 15 Participants

Primary: Number of Days of Alcohol Use — 0.71; 0.58; 0.70; 0.70 days

Primary: Rate of Small for Gestational Age at Birth Identified Antenatally — 28; 46 Participants

Primary: Progression-free Survival (PFS) — 5.29; 5.55; 3.76 months — p=0.3293

Primary: Child Immunization Status at 19 Months, 0 Days of Age Characterized as Percent Days Under-immunized (DUI) — 32; 24 percentage of days under-immunized — p=0.9